Wells Fargo Upgrades Celldex Therapeutics (CLDX) to Equal Weight

Wells Fargo analyst Derek Archila upgraded Celldex Therapeutics (NASDAQ: CLDX) from Underweight to Equal Weight with a price target of $27.00.

For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.

Shares of Celldex Therapeutics closed at $25.78 yesterday.

You May Also Be Interested In

• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Kepler Cheuvreux Upgrades Swissquote Group Holding SA (SQN:SW) to Buy
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy